Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Radiation With 5-ALA in Advanced Malignancies
NCT04381806Phase 1Suspended
- Sponsor
- Fox Chase Cancer Center
- Start
- Jul 2020
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 5-aminolevulinic acid in solid tumor, sponsored by Fox Chase Cancer Center. Primary endpoint: Maximum Tolerated Dose at 45 days. Started Jul 2020; status: suspended.
02
Drugs
5-aminolevulinic acid
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04381806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04381806.